Sexual Satisfaction Results With the Vaginal pH Modulator From the Phase 3 AMPOWER Study
The Journal of Sexual Medicine has published data from EVFM’s Phase 3 AMPOWER registration trial demonstrating that 88.7% of women using Phexxi improved or maintained their sex life. “Phexxi offered the women in this study a non-hormonal, woman-controlled, on-demand contraceptive gel that clearly provided a unique set of positive benefits on their sexual health and enjoyment,” said Dr. Todd Chappell, a lead investigator on the AMPOWER study and practicing obstetrician and gynecologist.
March 2022
Click for full info +Full Info:
Resource Type:
Media / News Article
Press Release
Authors:
Michael A. Thomas, MD, Robert Morlock, PhD, Clint Dart, MS, and Brandon Howard, PhD
Health Risks(s):
- Unintended Pregnancy
Product type(s):
- MPTs
- VaginalCream
Topic(s):
- MPTs
- Development
- Reproductive Health
- Social
Region(s)
- United States
URL of resource: